Research Areas
Biography and Research Information
OverviewAI-generated summary
AbdelHai Hammo's research focuses on the clinical effectiveness and safety of ustekinumab in pediatric and adolescent patients diagnosed with refractory inflammatory bowel disease. His work includes retrospective cohort studies examining treatment outcomes in these young populations. Hammo has published on the efficacy and safety of ustekinumab in youth with inflammatory bowel disease, with a particular emphasis on outcomes in specific geographic regions. His scholarship metrics include an h-index of 1 with 2 total publications and 8 total citations.
Metrics
- h-index: 1
- Publications: 2
- Citations: 8
Selected Publications
-
Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study (2024)
-
A222 CLINICAL EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN YOUTH WITH REFRACTORY INFLAMMATORY BOWEL DISEASE IN SAUDI ARABIA: A RETROSPECTIVE COHORT STUDY (2024)
Collaboration Network
Top Collaborators
- Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study
- A222 CLINICAL EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN YOUTH WITH REFRACTORY INFLAMMATORY BOWEL DISEASE IN SAUDI ARABIA: A RETROSPECTIVE COHORT STUDY
- A222 CLINICAL EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN YOUTH WITH REFRACTORY INFLAMMATORY BOWEL DISEASE IN SAUDI ARABIA: A RETROSPECTIVE COHORT STUDY
- A222 CLINICAL EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN YOUTH WITH REFRACTORY INFLAMMATORY BOWEL DISEASE IN SAUDI ARABIA: A RETROSPECTIVE COHORT STUDY
- Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study
- Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study
Similar Researchers
Based on overlapping research topics